Comprehensive Analysis of *HEXB* Protein Reveal Forty Two Novel nsSNPs That May Lead to Sandhoff disease (SD) Using Bioinformatics

Tebyan A. Abdelhameed¹, Mosab M. Gasmelseed¹, Mujahed I. Mustafa^{1,2}, Dina N. Abdelrahman^{1,3}, Fatima A. Abdelrhman¹, Mohamed A. Hassan¹.

1. Department of biotechnology, Africa City of Technology-Khartoum, Sudan.

2. Department of Biochemistry, University of Bahri-Khartoum, Sudan.

3. Central laboratory, Ministry of Higher education and scientific research- Khartoum, Sudan.

Corresponding author: Tebyan A. Abdelhameed: tebyanameer2511@gmail.com.

ABSTRACT

Background: Single Nucleotide Polymorphisms (SNPs) in the *HEXB* gene are associated with a neurodegenerative disorder called Sandhoff disease (SD) (GM2 gangliosidosis-O variant). This study aimed to predict the possible pathogenic SNPs of this gene and their impact on the protein using different bioinformatics tools. **Methods:** SNPs retrieved from the NCBI database were analyzed using several bioinformatics tools. The different algorithms collectively predicted the effect of single nucleotide substitution on both structure and function of beta subunit beta subunit of both hexosaminidase A and hexosaminidase B proteins. **Results:** Forty nine mutations were found to be extremely damaging to the structure and function of the *HEXB* gene protein.

Conclusion: According to this study, forty two novel nsSNP in *HEXB* are predicted to have possible role in Sandhoff disease using different bioinformatics tools, beside two SNPs found to have effect on miRNAs binding site affecting expression of *HEXB* gene. Our findings may assist in genetic study and diagnosis of Sandhoff disease.

Keywords: *Sandhoff disease (SD), GM2 gangliosidosis, hexosaminidase A, HEXB, a neurodegenerative disorder, bioinformatics, single nucleotide polymorphisms (SNPs), computational, insilico*

1. INTRODUCTION:

Sandhoff disease (SD) also called (GM2 gangliosidosis-O variant) is a fatal rare autosomal recessive lysosomal storage disease of sphingolipid (GM2 ganglioside GM2) metabolism resulting from the deficiency of β -hexosaminidase (HexB) (1-5). The estimated carrier frequency of SD with a high incidence among certain isolated communities and ethnic groups around the world such as in Saskatchewan at rate 1:15 (1, 6). It is caused by deficiency of N-acetyl- β -hexosaminidase (Hex) resulting in pathological accumulation of GM2 ganglioside in lysosomes of the central nervous system (CNS) and progressive neurodegeneration. Currently, there is no treatment for SD. (2, 7) Affected individuals present with a wide spectrum of clinical manifestations, ranging from psychomotor impairment and death in the infantile form to motor neuron disease and autonomic dysfunction in the adult form(8) The disorder is classified according to the age of onset, as infantile, juvenile and adult form.(5) The most common and severe form of Sandhoff disease becomes apparent in infancy,(9-13) The clinical features of juvenile SD include ataxia, dysarthria and cerebellar atrophy , develop early and severe sensory loss in addition to chronic motor neuron disease and cerebellar ataxia(14) While the clinical features of adult SD include progressive muscle cramps, as well as wasting and weakness of the legs with onset after age 20. They also can show intention tremor of the upper extremities and dysarthria.(8)

The *HEXB* gene provides instructions for making a protein that is a subunit of two related enzymes; beta-hexosaminidase A and beta-hexosaminidase B. play a critical role in the central nervous system, These enzymes are found in lysosomes. Within lysosomes, the enzymes break down sphingolipids, oligosaccharides, and molecules that are linked to sugars such as glycoproteins (15) . *HEXB* gene is localized on 5q13.3, which is the long (q) arm of chromosome 5 at position 13.3. The disease is caused by mutation in *HEXB* encoding the β -subunit of β -hexosaminidase A. β -Hexosaminidase A exists as a heterodimer consisting of α - and β -subunits (16). Numerous studies in the past have shown that SNPs are responsible of mutations that lead to cause Sandhoff disease (16, 17) . Single nucleotide polymorphisms (SNPs) are an important source of human genome variability. Non-synonymous SNPs occurring in coding regions result in single amino acid polymorphisms (SAPs) that may affect protein function and lead to pathology (18) . Functional variations can have deleterious or neutral effects on protein structure or function (19) Damaging effects might include destabilization of protein structure, altering gene regulation (20) affecting protein charge, geometry, hydrophobicity(21), stability, dynamics, translation and inter/intra protein interactions. (22, 23) , hence structural integrity of cells comes under risk (24). Thus it can be avowed that nsSNPs might get linked with many human diseases because of these missense SNPs.(25) The aim of this study was to identify the possible pathogenic SNPs in *HEXB* gene using in silico prediction software, and to determine the structure, function and regulation of their respective proteins. This is the first study which covers an extensive in silico analysis of nsSNPs of HEXB protein hence this work might be useful in

future in developing precision medicines for the treatment of diseases caused by these genomic variations. (26)

2. MATERIALS AND MEYHODS:

2.1 Data mining:

The data on human *HEXB* gene was collected from National Center for Biological Information (NCBI) web site (27) . The SNP information (protein accession number and SNP ID) of the MEFV gene was retrieved from the NCBI dbSNP (<http://www.ncbi.nlm.nih.gov/snp/>) and the protein sequence was collected from Swiss Prot databases (<http://expasy.org/>). (28)

2.2 SIFT:

SIFT is a sequence homology-based tool (29) that sorts intolerant from tolerant amino acid substitutions and predicts whether an aminoacid substitution in a protein will have a phenotypic Effect. Considers the position at which the change occurred and the type of amino acid change. Given a protein sequence, SIFT chooses related proteins and obtains an alignment of these proteins with the query. Based on the amino acids appearing at each position in the alignment, SIFT calculates the probability that an amino acid at a position is tolerated conditional on the most frequent amino acid being tolerated. If this normalized value is less than a cutoff, the substitution is predicted to be deleterious. SIFT scores <0.05 are predicted by the algorithm to be intolerant or deleterious amino acid substitutions, whereas scores >0.05 are considered tolerant. It is available at (<http://sift.bii.a-star.edu.sg/>).

2.3 Polyphen-2:

It is a software tool (30) to predict possible impact of an amino acid substitution on both structure and function of a human protein by analysis of multiple sequence alignment and protein 3D structure, in addition it calculates position-specific independent count scores (PSIC) for each of two variants, and then calculates the PSIC scores difference between two variants. The higher a PSIC score difference, the higher the functional impact a particular amino acid substitution is likely to have. Prediction outcomes could be classified as probably damaging, possibly damaging or benign according to the value of PSIC as it ranges from (0_1); values closer to zero considered benign while values closer to 1 considered probably damaging and also it can be indicated by a vertical black marker inside a color gradient bar, where green is benign and red is damaging. nsSNPs that predicted to be intolerant by Sift has been submitted to Polyphen as protein sequence in FASTA format that obtained from UniprotKB /Expasy after submitting the relevant ensemble protein (ESNP) there, and then we entered position of mutation, native amino acid and the new substituent for both structural and functional predictions. PolyPhen version 2.2.2 is available at (<http://genetics.bwh.harvard.edu/pph2/index.shtml>).

2.4 Provean:

Provean is a software tool (31) which predicts whether an amino acid substitution or indel has an impact on the biological function of a protein. It is useful for filtering sequence variants to identify nonsynonymous or indel variants that are predicted to be functionally important. It is available at (<https://roslab.org/services/snap2web/>).

2.5 SNAP2:

Functional effects of mutations are predicted with SNAP2 (32). SNAP2 is a trained classifier that is based on a machine learning device called "neural network". It distinguishes between effect and neutral variants/non-synonymous SNPs by taking a variety of sequence and variant features into account. The most important input signal for the prediction is the evolutionary information taken from an automatically generated multiple sequence alignment. Also structural features such as predicted secondary structure and solvent accessibility are considered. If available also annotation (i.e. known functional residues, pattern, regions) of the sequence or close homologs are pulled in. In a cross-validation over 100,000 experimentally annotated variants, SNAP2 reached sustained two-state accuracy (effect/neutral) of 82% (at an AUC of 0.9). In our hands this constitutes an important and significant improvement over other methods. It is available at (<https://roslab.org/services/snap2web/>).

2.6 PHD-SNP:

An online Support Vector Machine (SVM) based classifier, is optimized to predict if a given single point protein mutation can be classified as disease-related or as a neutral polymorphism, it is available at: (<http://http://snps.biofold.org/phd-snp/phdsnp.html>).

2.7 SNP& Go:

SNPs&GO is an accurate method that, starting from a protein sequence, can predict whether a variation is disease related or not by exploiting the corresponding protein functional annotation. SNPs&GO collects in unique framework information derived from protein sequence, evolutionary information, and function as encoded in the Gene Ontology terms, and outperforms other available predictive methods. (33) It is available at (<http://snps.biofold.org/snps-and-go/snps-and-go.html>)

2.8 P-Mut:

PMUT a web-based tool (34) for the annotation of pathological variants on proteins, allows the fast and accurate prediction (approximately 80% success rate in humans) of the pathological character of single point amino acidic mutations based on the use of neural networks. It is available at (<http://mmb.irbbarcelona.org/PMut>).

2.9 I-Mutant 3.0:

I-Mutant 3.0 Is a neural network based tool (35) for the routine analysis of protein stability and alterations by taking into account the single-site mutations. The FASTA sequence of protein retrieved from UniProt is used as an input to predict the mutational effect on protein stability. It is available at (<http://gpcr2.biocomp.unibo.it/cgi/predictors/I-Mutant3.0/I-Mutant3.0.cgi>).

2.10 Project Hope:

Online software is available at: (<http://www.cmbi.ru.nl/hope/method/>). It is a web service where the user can submit a sequence and mutation. The software collects structural information from a series of sources, including calculations on the 3D protein structure, sequence annotations in UniProt and prediction from other software. It combines this information to give analysis for the effect of a certain mutation on the protein structure. HOPE will show the effect of that mutation in such a way that even those without a bioinformatics background can understand it. It allows the user to submit a protein sequence (can be FASTA or not) or an accession code of the protein of interest. In the next step, the user can indicate the mutated residue with a simple mouse click. In the final step, the user can simply click on one of the other 19 amino acid types that will become the mutant residue, and then full report well is generated (36).

2.12 Raptor X

RaptorX (<http://raptorx.uchicago.edu/>): It is a web server predicting structure property of a protein sequence without using any templates. It outperforms other servers, especially for proteins without close homologs in PDB or with very sparse sequence profile. The server predicts tertiary structure (37)

2.11 UCSF Chimera (University of California at San Francisco):

UCSF Chimera (<https://www.cgl.ucsf.edu/chimera/>) is a highly extensible program for interactive visualization and analysis of molecular structures and related data, including density maps, supramolecular assemblies, sequence alignments, docking results, trajectories, and conformational ensembles. High-quality images and animations can be generated. Chimera includes complete documentation and several tutorials. Chimera is developed by the Resource for Biocomputing, Visualization, and Informatics (RBVI), supported by the National Institutes of Health (P41-GM103311).(38)

2.12 PolymiRTS:

PolymiRTS is a software used to predict 3UTR (un-translated region) polymorphism in microRNAs and their target sites available at (<http://compbio.uthsc.edu/miRSNP/>). It is a database of naturally occurring DNA variations in microRNAs (miRNA) seed region and miRNA target sites. MicroRNAs pair to the transcript of protein coding genes and cause translational repression or mRNA destabilization. SNPs in microRNA and their target sites may affect miRNA-mRNA interaction, causing an effect on miRNA-mediated gene repression, PolymiRTS database was created by scanning 3UTRs of mRNAs in human and mouse for SNPs in miRNA target sites. Then, the effect of polymorphism on gene expression and phenotypes are

identified and then linked in the database. The PolymiRTS data base also includes polymorphism in target sites that have been supported by a variety of experimental methods and polymorphism in miRNA seed regions. (39)

2.13 GeneMANIA:

It is gene interaction software that finds other genes which is related to a set of input genes using a very large set of functional association data. Association data include protein and genetic interactions, pathways, co-expression, co-localization and protein domain similarity. GeneMANIA also used to find new members of a pathway or complex, find additional genes you may have missed in your screen or find new genes with a specific function, such as protein kinases. available at (<https://genemania.org/>) (40).

3. RESULTS:

3.1 The functional effect of Deleterious and damaging nsSNPs of HEXB by SIFT, Provean PolyPhen-2, and SNAP2

Table (1): Damaging or Deleterious or effect nsSNPs associated variations predicted by SIFT, Provean PolyPhen-2, and SNAP2 softwares:

dbSNP rs#	SUB	SIFT prediction	Score	Polyphen prediction	Score	Prediction (cutoff= -2.5)	PROVEAN score	SNAP2 prediction	Score
rs766282406	W166C	D	0	probably damaging	1	Deleterious	-12.526	effect	31
rs1205668888	G167R	D	0	probably damaging	1	Deleterious	-7.708	effect	95
rs951616685	G167A	D	0	probably damaging	1	Deleterious	-5.781	effect	84
rs759538325	R170Q	D	0	probably damaging	1	Deleterious	-3.654	effect	72
rs976468812	F175C	D	0	probably damaging	1	Deleterious	-7.708	effect	4
rs398123449	D196A	D	0	probably damaging	1	Deleterious	-7.708	effect	63
rs752621035	R199G	D	0	probably damaging	1	Deleterious	-6.745	effect	75
rs762821794	G204E	D	0	probably damaging	1	Deleterious	-7.708	effect	85
rs761538803	R211T	D	0	probably damaging	1	Deleterious	-5.779	effect	90
rs367963796	L223P	D	0	probably damaging	1	Deleterious	-6.643	effect	77
rs1050332517	N232H	D	0	probably damaging	1	Deleterious	-4.873	effect	61
rs1375560334	L234R	D	0	probably damaging	1	Deleterious	-4.4	effect	65
rs1258632902	H237R	D	0	probably damaging	1	Deleterious	-7.797	effect	77
rs1301523493	P245L	D	0	probably damaging	1	Deleterious	-9.663	effect	52
rs771103635	L254S	D	0	probably damaging	1	Deleterious	-5.846	effect	45
rs373979283	Y266D	D	0	probably damaging	1	Deleterious	-9.403	effect	92

rs398123450	Y266C	D	0	probably damaging	1	Deleterious	-8.495	effect	68
rs750645495	E288Q	D	0	probably damaging	1	Deleterious	-2.806	effect	84
rs866283559	D290N	D	0	probably damaging	1	Deleterious	-4.71	effect	80
rs1200101608	G293R	D	0	probably damaging	1	Deleterious	-7.536	effect	87
rs1439544901	W298C	D	0	probably damaging	1	Deleterious	-11.813	effect	24
rs1189912520	G301D	D	0	probably damaging	1	Deleterious	-6.585	effect	50
rs1252744810	L305P	D	0	probably damaging	1	Deleterious	-6.474	effect	74
rs773315856	F344S	D	0	probably damaging	1	Deleterious	-7.676	effect	70
rs751352339	H350D	D	0	probably damaging	1	Deleterious	-8.621	effect	92
rs781244479	D354A	D	0	probably damaging	1	Deleterious	-7.676	effect	85
rs781244479	D354G	D	0	probably damaging	1	Deleterious	-6.724	effect	91
rs1245724719	C360Y	D	0	probably damaging	1	Deleterious	-10.553	effect	53
rs779364743	W361R	D	0	probably damaging	1	Deleterious	-13.153	effect	87
rs753450688	W405R	D	0	probably damaging	1	Deleterious	-13.495	effect	95
rs984639297	P468H	D	0	probably damaging	1	Deleterious	-8.462	effect	56
rs760333736	G483D	D	0	probably damaging	1	Deleterious	-6.504	effect	80
rs760333736	G483V	D	0	probably damaging	1	Deleterious	-8.362	effect	80
rs1447056657	W489R	D	0	probably damaging	1	Deleterious	-13.008	effect	95
rs754180181	E491G	D	0	probably damaging	1	Deleterious	-6.504	effect	86
-	V493G	D	0	probably damaging	1	Deleterious	-6.504	effect	54
rs121907985	P504S	D	0	probably damaging	1	Deleterious	-7.294	effect	91
-	R505W	D	0	probably damaging	1	Deleterious	-7.292	effect	90
rs1229725676	E511G	D	0	probably damaging	1	Deleterious	-6.382	effect	73
rs778501777	L513H	D	0	probably damaging	1	Deleterious	-6.382	effect	53
rs778501777	L513P	D	0	probably damaging	1	Deleterious	-6.382	effect	72
rs1417317737	W514C	D	0	probably damaging	1	Deleterious	-11.853	effect	77
rs760366178	R528I	D	0	probably damaging	1	Deleterious	-7.294	effect	77
rs745454291	L529R	D	0	probably damaging	1	Deleterious	-5.371	effect	69
rs764552042	R533C	D	0	probably damaging	1	Deleterious	-7.294	effect	63
rs727503960	C534F	D	0	probably damaging	1	Deleterious	-10.029	effect	23
rs749646826	R539C	D	0	probably damaging	1	Deleterious	-7.174	effect	32
rs769208361	R539H	D	0	probably damaging	1	Deleterious	-4.484	effect	61
rs727503961	C551Y	D	0	probably damaging	1	Deleterious	-9.773	effect	79

*SUB= Substitution

*D= Deleterious

3.2 Functional analysis of ADAMTS13 gene using Disease Related and pathological effect of nsSNPs by PhD-SNP, SNPs & GO and PMut softwares:

Table (2): Prediction of Disease Related and pathological effect of nsSNPs by PhD-SNP, SNPs & GO and PMut:

dbSNP rs#	SUB	SNP&Go Prediction	RI	Probability	PHD-SNP Prediction	RI	Probability	P-mut Prediction	Score
rs766282406	W166C	Disease	3	0.645	Disease	6	0.785	Disease	0.78 (88%)
rs1205668888	G167R	Disease	7	0.865	Disease	9	0.937	Disease	0.93 (94%)
rs951616685	G167A	Disease	6	0.805	Disease	7	0.852	Disease	0.80 (89%)
rs759538325	R170Q	Disease	5	0.734	Disease	5	0.732	Disease	0.82 (90%)
rs976468812	F175C	Disease	6	0.779	Disease	8	0.876	Disease	0.93 (94%)
rs398123449	D196A	Disease	7	0.861	Disease	8	0.9	Disease	0.92 (94%)
rs752621035	R199G	Disease	4	0.711	Disease	7	0.837	Disease	0.88 (92%)
rs762821794	G204E	Disease	7	0.846	Disease	8	0.903	Disease	0.85 (91%)
rs761538803	R211T	Disease	7	0.863	Disease	9	0.932	Disease	0.92 (94%)
rs367963796	L223P	Disease	7	0.841	Disease	9	0.951	Disease	0.93 (94%)
rs1050332517	N232H	Disease	7	0.829	Disease	9	0.94	Disease	0.93 (94%)
rs1375560334	L234R	Disease	9	0.934	Disease	9	0.969	Disease	0.92 (94%)
rs1258632902	H237R	Disease	8	0.88	Disease	9	0.948	Disease	0.91 (93%)
rs1301523493	P245L	Disease	4	0.704	Disease	6	0.795	Disease	0.87 (92%)
rs771103635	L254S	Disease	6	0.779	Disease	6	0.824	Disease	0.92 (94%)
rs373979283	Y266D	Disease	7	0.848	Disease	9	0.946	Disease	0.93 (94%)
rs398123450	Y266C	Disease	7	0.835	Disease	9	0.932	Disease	0.93 (94%)
rs750645495	E288Q	Disease	6	0.803	Disease	7	0.837	Disease	0.89 (92%)
rs866283559	D290N	Disease	4	0.711	Disease	7	0.843	Disease	0.82 (90%)
rs1200101608	G293R	Disease	7	0.848	Disease	8	0.892	Disease	0.93 (94%)
rs1439544901	W298C	Disease	3	0.63	Disease	5	0.773	Disease	0.84 (90%)
rs1189912520	G301D	Disease	3	0.659	Disease	6	0.779	Disease	0.76 (88%)
rs1252744810	L305P	Disease	7	0.836	Disease	8	0.899	Disease	0.91 (93%)
rs773315856	F344S	Disease	6	0.797	Disease	8	0.891	Disease	0.78 (88%)
rs751352339	H350D	Disease	6	0.821	Disease	8	0.898	Disease	0.92 (94%)
rs781244479	D354A	Disease	8	0.887	Disease	9	0.928	Disease	0.89 (92%)
rs781244479	D354G	Disease	7	0.857	Disease	8	0.918	Disease	0.93 (94%)
rs1245724719	C360Y	Disease	2	0.596	Disease	7	0.829	Disease	0.68 (85%)
rs779364743	W361R	Disease	7	0.856	Disease	9	0.936	Disease	0.93 (94%)
rs753450688	W405R	Disease	8	0.884	Disease	9	0.956	Disease	0.91 (93%)
rs984639297	P468H	Disease	4	0.703	Disease	7	0.861	Disease	0.77 (88%)
rs760333736	G483D	Disease	8	0.884	Disease	9	0.949	Disease	0.92 (94%)
rs760333736	G483V	Disease	7	0.874	Disease	9	0.941	Disease	0.93 (94%)
rs1447056657	W489R	Disease	8	0.895	Disease	9	0.97	Disease	0.93 (94%)
rs754180181	E491G	Disease	6	0.779	Disease	7	0.86	Disease	0.88 (92%)
-	V493G	Disease	4	0.697	Disease	6	0.822	Disease	0.74 (87%)
rs121907985	P504S	Disease	5	0.747	Disease	6	0.819	Disease	0.87 (91%)

-	R505W	Disease	7	0.827	Disease	8	0.893	Disease	0.91 (93%)
rs1229725676	E511G	Disease	4	0.68	Disease	4	0.723	Disease	0.87 (91%)
rs778501777	L513H	Disease	1	0.541	Disease	3	0.644	Disease	0.84 (90%)
rs778501777	L513P	Disease	6	0.804	Disease	6	0.819	Disease	0.84 (90%)
rs1417317737	W514C	Disease	7	0.83	Disease	8	0.891	Disease	0.92 (93%)
rs760366178	R528I	Disease	5	0.742	Disease	8	0.91	Disease	0.86 (91%)
rs745454291	L529R	Disease	4	0.696	Disease	8	0.908	Disease	0.85 (91%)
rs764552042	R533C	Disease	5	0.752	Disease	7	0.873	Disease	0.79 (89%)
rs727503960	C534F	Disease	5	0.75	Disease	6	0.794	Disease	0.65 (84%)
rs749646826	R539C	Disease	4	0.707	Disease	7	0.857	Disease	0.86 (91%)
rs769208361	R539H	Disease	0	0.516	Disease	4	0.69	Disease	0.59 (82%)
rs727503961	C551Y	Disease	3	0.672	Disease	8	0.893	Disease	0.88 (92%)

3.3 Prediction of Change in Stability due to Mutation Using I-Mutant 3.0 Server

Table (3): Prediction of nsSNPs Impact on Protein structure Stability by I-Mutant

dbSNP rs#	SNP	SVM2 Prediction Effect	DDG Value
rs766282406	W166C	Decrease Protein Stability	-1.64
rs1205668888	G167R	Decrease Protein Stability	-0.9
rs951616685	G167A	Decrease Protein Stability	-0.68
rs759538325	R170Q	Decrease Protein Stability	-0.84
rs976468812	F175C	Decrease Protein Stability	-1.58
rs398123449	D196A	Decrease Protein Stability	-1
rs752621035	R199G	Decrease Protein Stability	-1.64
rs762821794	G204E	Decrease Protein Stability	-0.94
rs761538803	R211T	Decrease Protein Stability	-0.74
rs367963796	L223P	Decrease Protein Stability	-1.81
rs1050332517	N232H	Decrease Protein Stability	-0.85
rs1375560334	L234R	Decrease Protein Stability	-1.74
rs1258632902	H237R	Decrease Protein Stability	-0.16

rs1301523493	P245L	Decrease Protein Stability	-0.37
rs771103635	L254S	Decrease Protein Stability	-2.11
rs373979283	Y266D	Decrease Protein Stability	-1.24
rs398123450	Y266C	Decrease Protein Stability	-1.41
rs750645495	E288Q	Decrease Protein Stability	-0.77
rs866283559	D290N	Decrease Protein Stability	-1.04
rs1200101608	G293R	Decrease Protein Stability	-0.31
rs1439544901	W298C	Decrease Protein Stability	-1.35
rs1189912520	G301D	Decrease Protein Stability	-0.81
rs1252744810	L305P	Decrease Protein Stability	-1.43
rs773315856	F344S	Decrease Protein Stability	-1.52
rs751352339	H350D	Increase Protein Stability	0.01
rs781244479	D354A	Decrease Protein Stability	-0.36
rs781244479	D354G	Increase Protein Stability	-0.86
rs1245724719	C360Y	Increase Protein Stability	-0.25
rs779364743	W361R	Decrease Protein Stability	-1.07
rs753450688	W405R	Decrease Protein Stability	-1.18
rs984639297	P468H	Decrease Protein Stability	-1.27
rs760333736	G483D	Decrease Protein Stability	-0.77
rs760333736	G483V	Decrease Protein Stability	-0.13
rs1447056657	W489R	Decrease Protein Stability	-1.08
rs754180181	E491G	Decrease Protein Stability	-1.2
-	V493G	Decrease Protein Stability	-2.58
rs121907985	P504S	Decrease Protein Stability	-1.7
-	R505W	Decrease Protein Stability	-0.34
rs1229725676	E511G	Decrease Protein Stability	-1.29
rs778501777	L513H	Decrease Protein Stability	-2.4
rs778501777	L513P	Decrease Protein Stability	-1.81
rs1417317737	W514C	Decrease Protein Stability	-1.66

rs760366178	R528I	Decrease Protein Stability	-0.39
rs745454291	L529R	Decrease Protein Stability	-1.77
rs764552042	R533C	Decrease Protein Stability	-1.05
rs727503960	C534F	Decrease Protein Stability	0.04
rs749646826	R539C	Decrease Protein Stability	-0.79
rs769208361	R539H	Decrease Protein Stability	-1.15
rs727503961	C551Y	Decrease Protein Stability	-0.06

3.4 SNPs effect on 3'UTR Region (miRNA binding sites) in HEXB using PolymiRTS Database

Table (6): prediction of SNPs sites in HEXB gene at the 3'UTR Region using PolymiRTS

Location	dbSNP ID	Variant	Wobble	Ancestral	Allele	miR ID	Conservation	miRSite	Function	Exp	context+
		type	base pair	Allele					Class	Support	score change
74017009	rs75974765	SNP	Y	G	G	hsa-miR-3679-3p	11	aatggaGGGAAA	D	N	No Change
					A	hsa-miR-204-5p	5	aatggAAGGGAAa	C	N	No Change
						hsa-miR-211-5p	5	aatggAAGGGAAa	C	N	No Change
						hsa-miR-4446-5p	11	aatggaAGGGAAA	C	N	No Change
						hsa-miR-4755-5p	5	aatggAAGGGAAA	C	N	No Change
						hsa-miR-5006-3p	5	aatggAAGGGAAA	C	N	No Change

74017022	rs1048088	SNP	N	A	C	hsa-miR-4731-5p	<u>2</u>	aaggC CC CAGCAa	C	N	-0.447
					C	hsa-miR-5589-5p	<u>3</u>	aaggcC CC CAGCAa	C	N	-0.19

3.5 Modeling of amino acid substitution effects on protein structure using

Figure 2: rs373979283 (Y226D) Effect of change in the amino acid position **226** from **Threonine** to **Aspartic Acid** on the **HEXB** protein 3D structure using Chimera Software.

Figure 3: rs121907985 (**P504S**) Effect of change in the amino acid position **504** from **Proline** into **Serine** on the **HEXB** protein 3D structure using Chimera Software.

Figure 4: rs764552042 (**R533C**) Effect of change in the amino acid position **533** from **Arginine** into **Cysteine** on the **HEXB** protein 3D structure using Chimera Software.

Interactions of *HEXB* gene with other Functional Genes illustrated by GeneMANIA

Figure 5: *HEXB* Gene Interactions and network predicted by GeneMania.

Table (4): The *HEXB* gene functions and its appearance in network and genome

Function	FDR	Genes in network	Genes in genome
lysosomal lumen	0.24213642	3	67
vacuolar lumen	0.24213642	3	69
positive regulation of calcium ion transmembrane transporter activity	0.24213642	2	14

chondroitin sulfate catabolic process	0.24213642	2	13
glycosphingolipid metabolic process	0.24213642	3	55
keratan sulfate catabolic process	0.24213642	2	12
positive regulation of cation channel activity	0.24213642	2	14
hyaluronan catabolic process	0.24213642	2	13
glycolipid metabolic process	0.264490442	3	91
sphingolipid metabolic process	0.303538365	3	102

Table (5): The gene co-expressed, share domain and Interaction with HEXA gene network

Gene 1	Gene 2	Weight	Network group	Network
<i>ASAH1</i>	<i>HEXB</i>	0.024078486	Co-expression	Ramaswamy-Golub-2001
<i>CAST</i>	<i>HEXB</i>	0.013190575	Co-expression	Ramaswamy-Golub-2001
<i>RAB27A</i>	<i>HEXB</i>	0.021869302	Co-expression	Ramaswamy-Golub-2001
<i>CD63</i>	<i>HEXB</i>	0.016662408	Co-expression	Ramaswamy-Golub-2001
<i>CD63</i>	<i>HEXA</i>	0.013731302	Co-expression	Ramaswamy-Golub-2001
<i>CD63</i>	<i>ASAH1</i>	0.016009336	Co-expression	Ramaswamy-Golub-2001
<i>CD63</i>	<i>RAB27A</i>	0.017109819	Co-expression	Ramaswamy-Golub-2001
<i>GYG1</i>	<i>HEXB</i>	0.008671436	Co-expression	Wang-Maris-2006
<i>ASAH1</i>	<i>HEXB</i>	0.01164002	Co-expression	Wang-Maris-2006
<i>CAST</i>	<i>HEXB</i>	0.009363974	Co-expression	Wang-Maris-2006
<i>CD63</i>	<i>HEXB</i>	0.00630279	Co-expression	Wang-Maris-2006
<i>CD63</i>	<i>GYG1</i>	0.011525528	Co-expression	Wang-Maris-2006
<i>HEXA</i>	<i>HEXB</i>	0.021510394	Co-expression	Mallon-McKay-2013
<i>CCPG1</i>	<i>HEXB</i>	0.017047796	Co-expression	Mallon-McKay-2013
<i>CTBS</i>	<i>CCPG1</i>	0.012258756	Co-expression	Mallon-McKay-2013
<i>CTBS</i>	<i>SERPINI1</i>	0.019850705	Co-expression	Bild-Nevins-2006 B
<i>HK2</i>	<i>ALDH1B1</i>	0.022080135	Co-expression	Burington-Shaughnessy-2008

<i>CTBS</i>	<i>GRB2</i>	0.007812744	Co-expression	Burington-Shaughnessy-2008
<i>CD63</i>	<i>SERPINI1</i>	0.00854729	Co-expression	Burington-Shaughnessy-2008
<i>CD63</i>	<i>CTBS</i>	0.008849712	Co-expression	Burington-Shaughnessy-2008
<i>ASAH1</i>	<i>SERPINI1</i>	0.012569555	Co-expression	Dobbin-Giordano-2005
<i>CCPG1</i>	<i>HEXB</i>	0.021864697	Co-expression	Dobbin-Giordano-2005
<i>RAB27A</i>	<i>HEXB</i>	0.020799356	Co-expression	Dobbin-Giordano-2005
<i>CTBS</i>	<i>HEXB</i>	0.01395548	Co-expression	Dobbin-Giordano-2005
<i>CTBS</i>	<i>CCPG1</i>	0.017793158	Co-expression	Dobbin-Giordano-2005
<i>CTBS</i>	<i>RAB27A</i>	0.01619344	Co-expression	Dobbin-Giordano-2005
<i>CAST</i>	<i>HEXB</i>	0.01447627	Co-expression	Bahr-Bowler-2013
<i>CD63</i>	<i>GYG1</i>	0.02225664	Co-expression	Bahr-Bowler-2013
<i>ASAH1</i>	<i>GYG1</i>	0.019104764	Co-expression	Innocenti-Brown-2011
<i>RAB27A</i>	<i>GYG1</i>	0.006233362	Co-expression	Innocenti-Brown-2011
<i>RAB27A</i>	<i>CCPG1</i>	0.006827028	Co-expression	Innocenti-Brown-2011
<i>IPO5</i>	<i>ALDH1B1</i>	0.005587121	Co-expression	Rieger-Chu-2004
<i>CAST</i>	<i>BNIP2</i>	0.016995838	Co-expression	Rieger-Chu-2004
<i>CD63</i>	<i>GYG1</i>	0.01405997	Co-expression	Rieger-Chu-2004
<i>CTBS</i>	<i>HEXB</i>	0.011450487	Co-expression	Noble-Diehl-2008
<i>CTBS</i>	<i>ASAH1</i>	0.019146528	Co-expression	Noble-Diehl-2008
<i>CCPG1</i>	<i>HEXB</i>	0.007359452	Co-expression	Roth-Zlotnik-2006
<i>RAB27A</i>	<i>CCPG1</i>	0.018139474	Co-expression	Roth-Zlotnik-2006
<i>CTBS</i>	<i>HEXB</i>	0.005897354	Co-expression	Roth-Zlotnik-2006
<i>CTBS</i>	<i>CCPG1</i>	0.013826602	Co-expression	Roth-Zlotnik-2006
<i>CD63</i>	<i>HEXB</i>	0.003053493	Co-expression	Roth-Zlotnik-2006
<i>ASAH1</i>	<i>SERPINI1</i>	0.008385506	Co-expression	Perou-Botstein-2000
<i>CAST</i>	<i>HEXB</i>	0.015681218	Co-expression	Perou-Botstein-2000
<i>CCPG1</i>	<i>SERPINI1</i>	0.012254277	Co-expression	Smirnov-Cheung-2009
<i>CTBS</i>	<i>BNIP2</i>	0.007756564	Co-expression	Smirnov-Cheung-2009
<i>CD63</i>	<i>HEXB</i>	0.013617347	Co-expression	Smirnov-Cheung-2009

<i>IPO5</i>	<i>RPL22</i>	0.012078757	Co-expression	Wang-Cheung-2015
<i>CD63</i>	<i>HEXB</i>	0.008066914	Co-expression	Wang-Cheung-2015
<i>ASAH1</i>	<i>HEXB</i>	0.023330089	Co-expression	Chen-Brown-2002
<i>CTBS</i>	<i>STIM2</i>	0.011675326	Co-expression	Perou-Botstein-1999
<i>GLS</i>	<i>HEXB</i>	0.005058561	Co-expression	Wu-Garvey-2007
<i>GLS</i>	<i>SERPINI1</i>	0.014305156	Co-expression	Wu-Garvey-2007
<i>ALDH1B1</i>	<i>HEXB</i>	0.006169923	Co-expression	Wu-Garvey-2007
<i>HK2</i>	<i>HEXB</i>	0.005873893	Co-expression	Wu-Garvey-2007
<i>CD63</i>	<i>HEXA</i>	0.010798354	Co-localization	Schadt-Shoemaker-2004
<i>CD63</i>	<i>ALDH1B1</i>	0.00954906	Co-localization	Schadt-Shoemaker-2004
<i>HEXA</i>	<i>HEXB</i>	0.005979959	Co-localization	Johnson-Shoemaker-2003
<i>GYG1</i>	<i>STIM1</i>	0.007238485	Co-localization	Johnson-Shoemaker-2003
<i>CAST</i>	<i>GYG1</i>	0.004685127	Co-localization	Johnson-Shoemaker-2003
<i>CTBS</i>	<i>HEXB</i>	0.008465399	Co-localization	Johnson-Shoemaker-2003
<i>CD63</i>	<i>HEXA</i>	0.008026743	Co-localization	Johnson-Shoemaker-2003
<i>BNIP2</i>	<i>HEXB</i>	0.4508404	Physical Interactions	Kristensen-Foster-2012
<i>RPL22</i>	<i>HEXB</i>	0.1588352	Physical Interactions	Kristensen-Foster-2012
<i>ALDH1B1</i>	<i>HEXB</i>	0.12618154	Physical Interactions	Kristensen-Foster-2012
<i>IPO5</i>	<i>HEXB</i>	0.093262665	Physical Interactions	Kristensen-Foster-2012
<i>HK2</i>	<i>HEXB</i>	0.06835952	Physical Interactions	Kristensen-Foster-2012
<i>HK2</i>	<i>IPO5</i>	0.121480554	Physical Interactions	Kristensen-Foster-2012
<i>STIM1</i>	<i>HEXB</i>	0.6925315	Physical Interactions	Wan-Emili-2015
<i>STIM2</i>	<i>HEXB</i>	0.3523203	Physical Interactions	Wan-Emili-2015
<i>STIM2</i>	<i>HEXA</i>	0.7962252	Physical Interactions	Wan-Emili-2015
<i>GRB2</i>	<i>HEXB</i>	0.14996375	Physical Interactions	Wan-Emili-2015
<i>STIM2</i>	<i>STIM1</i>	0.8585416	Physical Interactions	BIOGRID-SMALL-SCALE-STUDIES
<i>STIM2</i>	<i>STIM1</i>	0.2683295	Physical Interactions	IREF-INTACT
<i>CAST</i>	<i>GRB2</i>	0.010464651	Physical Interactions	IREF-INTACT
<i>CAST</i>	<i>GRB2</i>	0.016936215	Physical Interactions	Wu-Li-2007

<i>STIM2</i>	<i>STIM1</i>	1	Physical Interactions	IREF-HPRD
<i>HEXA</i>	<i>HEXB</i>	0.76536685	Predicted	Wu-Stein-2010
<i>STIM2</i>	<i>STIM1</i>	1	Predicted	Wu-Stein-2010
<i>SERPINI1</i>	<i>HEXB</i>	0.8312539	Predicted	Stuart-Kim-2003
<i>GLS</i>	<i>HEXB</i>	0.29914758	Predicted	Stuart-Kim-2003
<i>GYG1</i>	<i>HEXB</i>	0.5665604	Predicted	I2D-IntAct-Fly2Human
<i>IPO5</i>	<i>GYG1</i>	0.17434177	Predicted	I2D-IntAct-Fly2Human
<i>HEXA</i>	<i>HEXB</i>	0.1421952	Shared protein domains	INTERPRO
<i>STIM2</i>	<i>STIM1</i>	0.03625844	Shared protein domains	INTERPRO
<i>RP11-106M3.2</i>	<i>HEXB</i>	0.1104058	Shared protein domains	INTERPRO
<i>RP11-106M3.2</i>	<i>HEXA</i>	0.1104058	Shared protein domains	INTERPRO
<i>HEXDC</i>	<i>HEXB</i>	0.05014918	Shared protein domains	INTERPRO
<i>HEXDC</i>	<i>HEXA</i>	0.05014918	Shared protein domains	INTERPRO
<i>HEXDC</i>	<i>RP11-106M3.2</i>	0.05154457	Shared protein domains	INTERPRO
<i>CTBS</i>	<i>HEXB</i>	0.013065673	Shared protein domains	INTERPRO
<i>CTBS</i>	<i>HEXA</i>	0.013065673	Shared protein domains	INTERPRO
<i>CTBS</i>	<i>RP11-106M3.2</i>	0.013429452	Shared protein domains	INTERPRO
<i>CTBS</i>	<i>HEXDC</i>	0.014957326	Shared protein domains	INTERPRO
<i>HEXA</i>	<i>HEXB</i>	0.3798553	Shared protein domains	PFAM
<i>STIM2</i>	<i>STIM1</i>	0.05877976	Shared protein domains	PFAM
<i>RP11-106M3.2</i>	<i>HEXB</i>	0.3798553	Shared protein domains	PFAM
<i>RP11-106M3.2</i>	<i>HEXA</i>	0.3798553	Shared protein domains	PFAM
<i>HEXDC</i>	<i>HEXB</i>	0.28301316	Shared protein domains	PFAM
<i>HEXDC</i>	<i>HEXA</i>	0.28301316	Shared protein domains	PFAM
<i>HEXDC</i>	<i>RP11-106M3.2</i>	0.28301316	Shared protein domains	PFAM

4. DISSCUTION:

42 novel nsSNPs were identified out of 49 most damaging nsSNPs in the *HEXB* gene retrieved by our analysis using different bioinformatics tools which they could have adverse effects on the resulting protein fractionally and structurally.

The variant rs373979283 which entails the substitution Y266D was previously reported in patients with Sandoff disease(41-43), was predicted to be deleterious by all of the softwares used in this study in spite of the fact that Tyrosine is not highly conserved at this position because other homologous sequences were observed having other residues at the same position, but none of them is similar to Aspartate in terms of physiochemical properties, because Aspartate is smaller and less hydrophobic than Tyrosine, which could affect the protein folding process, in addition to that Tyrosine is neutral while Aspartate is negative in charge, therefore, this mutation could still be damaging.

The rs121907985 variant results in converting Proline into Serine which is smaller and less hydrophobic amino acid at the position 504, the difference in size could cause an empty space in the core of the protein, and the internal hydrophobic interactions could be lost because of the difference in the hydrophobicity value. Moreover, Proline's rigidity could be crucial to induce a special backbone conformation at this position which can be disturbed by this substitution. This mutation is annotated to be pathogenic in ClinVar and ExPASy databases, and was previously reported by Hou *et al.*(1998) in two sisters with Sandoff disease, they found that this mutation significantly increases precursor/mature ratio as a result of increasing the retention of newly synthesized protein in the Endoplasmic reticulum, and also lowers its heat stability(44). The P504S substitution is mostly linked to chronic and less severe forms of the disease (45).

The variant rs764552042 marks the substitution from Arginine to Cysteine at the position 533 (R533C), the mutant residue is neutral in charge, smaller and less hydrophobic than the wild residue which is positive in charge. The difference in charge and size could possibly have some detrimental effects on external interactions and interactions with internal molecules. The same mutation was previously reported in many countries in patients with Sandoff disease (13, 46-48). Zampieri *et al.*(2012) found that the activity of the affected protein is considerably diminished or completely absent compared to the normal protein, and they predicted the mutant residue C533 could form a disulphide bond with C551 which normally forms this bond with C534, and that could result in severe misfolding of the C terminal loop of the protein(49).

All the three mentioned SNPs reside at [IPR025705](#) and [IPR017853](#) domains, in addition to [IPR015883](#) for Y266D, P504S and R533C. These three domains are crucial for normal protein function and they interact with each other, which mean any mutation with deleterious effects within those domains could directly disturb the normal protein functionality.

Two SNPs ([rs75974765](#) and [rs1048088](#)) were found to have an effect in 3'UTR. [rs75974765](#) SNP is predicted to disrupt binding site of hsa-miR-3679-3p miRNA and creating new binding site at hsa-miR-204-5p , hsa-miR-211-5p , hsa-miR-4446-5p , hsa-miR-4755-5p and hsa-miR-5006-3p miRNAs while [rs1048088](#) SNP is predicted to creat new binding site at hsa-miR-4731-5p hsa-miR-5589-5p miRNAs . Both of those SNPs might result in expression of the gene.

The importance of this study relies on the fact that it has subjected all the reported variants within the *HEXB* gene for computational functional and structural analysis which might facilitate further association studies. However, there are some limitations to be considered, like the highly selective protocol which might lead to missing some important SNPs. Computational analysis provides a good insight into which SNPs could drastically affect the protein's tertiary structure and function, but it's not completely conclusive, as such, we recommend following this study with wet-lab functional genetic studies and gene knockout on real animal models.

5. CONCLUSION:

This study revealed 42 novel nsSNP out of 49 damaging SNPs in the *HEXB* gene affecting its function, structure and stability which they possibly lead to Sandhoff disease, by using different bioinformatics tools. Also, 2 SNPs found to have effect on miRNAs binding site affecting expression of HEXB gene. Optimistically, these results will aid in genetic studying and diagnosis of Sandhoff disease improvement.

6. ACKNOWLEDGMENT:

The authors desire to acknowledge the exciting collaboration of Africa City of Technology – Sudan.

7. DATA AVAILABILITY:

All relevant data used to support the findings of this study are included within the manuscript and supplementary information files.

8. CONFLICT OF INTEREST:

The authors declare that there is no conflict of interest regarding the publication of this paper.

References:

1. Fitterer B, Hall P, Antonishyn N, Desikan R, Gelb M, Lehotay D. Incidence and carrier frequency of Sandhoff disease in Saskatchewan determined using a novel substrate with detection by tandem mass spectrometry and molecular genetic analysis. *Molecular genetics and metabolism*. 2014;111(3):382-9.
2. Tay SK, Low PS, Ong HT, Loke KY. Sandhoff disease--a case report of 3 siblings and a review of potential therapies. *Annals of the Academy of Medicine, Singapore*. 2000;29(4):514-7.
3. Grunseich C, Schindler AB, Chen KL, Bakar D, Mankodi A, Traslavina R, et al. Peripheral neuropathy in a family with Sandhoff disease and SH3TC2 deficiency. *Journal of neurology*. 2015;262(4):1066-8.
4. Zhang W, Zeng H, Huang Y, Xie T, Zheng J, Zhao X, et al. Clinical, biochemical and molecular analysis of five Chinese patients with Sandhoff disease. *Metabolic brain disease*. 2016;31(4):861-7.
5. Eguchi I, Wakamatsu N, Nakano R, Tsuji S. [Lysosome disease--Sandhoff disease]. *Nihon rinsho Japanese journal of clinical medicine*. 1993;51(9):2276-80.
6. Fitterer BB, Antonishyn NA, Hall PL, Lehotay DC. A polymerase chain reaction-based genotyping assay for detecting a novel Sandhoff disease-causing mutation. *Genetic testing and molecular biomarkers*. 2012;16(5):401-5.
7. McCurdy VJ, Rockwell HE, Arthur JR, Bradbury AM, Johnson AK, Randle AN, et al. Widespread correction of central nervous system disease after intracranial gene therapy in a feline model of Sandhoff disease. *Gene therapy*. 2015;22(2):181-9.
8. Rubin M, Karpatis G, Wolfe LS, Carpenter S, Klavins MH, Mahuran DJ. Adult onset motor neuronopathy in the juvenile type of hexosaminidase A and B deficiency. *Journal of the neurological sciences*. 1988;87(1):103-19.
9. Wu T, Li X, Wang Q, Liu Y, Ding Y, Song J, et al. [HEXB gene study and prenatal diagnosis for a family affected by infantile Sandhoff disease]. *Zhejiang da xue xue bao Yi xue ban = Journal of Zhejiang University Medical sciences*. 2013;42(4):403-10.
10. Sakpichaisakul K, Taeranawich P, Nitiapinyasakul A, Sirisopikun T. Identification of Sandhoff disease in a Thai family: clinical and biochemical characterization. *Journal of the Medical Association of Thailand = Chotmaihet thangphaet*. 2010;93(9):1088-92.
11. Beker-Acay M, Elmas M, Koken R, Unlu E, Bukulmez A. Infantile Type Sandhoff Disease with Striking Brain MRI Findings and a Novel Mutation. *Polish journal of radiology*. 2016;81:86-9.
12. Jain A, Kohli A, Sachan D. Infantile Sandhoff's disease with peripheral neuropathy. *Pediatric neurology*. 2010;42(6):459-61.
13. Aryan H, Aryani O, Banihashemi K, Zaman T, Houshmand M. Novel Mutations in Sandhoff Disease: A Molecular Analysis among Iranian Cohort of Infantile Patients. *Iranian journal of public health*. 2012;41(3):112-8.
14. Schnorf H, Gitzelmann R, Bosshard NU, Spycher M, Waespe W. Early and severe sensory loss in three adult siblings with hexosaminidase A and B deficiency (Sandhoff disease). *Journal of neurology, neurosurgery, and psychiatry*. 1995;59(5):520-3.
15. Bateman KS, Cherney MM, Mahuran DJ, Tropak M, James MN. Crystal structure of beta-hexosaminidase B in complex with pyrimethamine, a potential pharmacological chaperone. *Journal of medicinal chemistry*. 2011;54(5):1421-9.
16. Yasui N, Takaoka Y, Nishio H, Nurputra DK, Sekiguchi K, Hamaguchi H, et al. Molecular pathology of Sandhoff disease with p.Arg505Gln in HEXB: application of simulation analysis. *Journal of human genetics*. 2013;58(9):611-7.

17. Jamali S, Eskandari N, Aryani O, Salehpour S, Zaman T, Kamalidehghan B, et al. Three novel mutations in Iranian patients with Tay-Sachs disease. *Iranian biomedical journal*. 2014;18(2):114-9.
18. Lander ES. The new genomics: global views of biology. *Science* (New York, NY). 1996;274(5287):536-9.
19. Capriotti E, Altman RB. Improving the prediction of disease-related variants using protein three-dimensional structure. *BMC bioinformatics*. 2011;12 Suppl 4:S3.
20. Barroso I, Gurnell M, Crowley VE, Agostini M, Schwabe JW, Soos MA, et al. Dominant negative mutations in human PPARgamma associated with severe insulin resistance, diabetes mellitus and hypertension. *Nature*. 1999;402(6764):880-3.
21. Petukh M, Kucukkal TG, Alexov E. On human disease-causing amino acid variants: statistical study of sequence and structural patterns. *Human mutation*. 2015;36(5):524-34.
22. Chasman D, Adams RM. Predicting the functional consequences of non-synonymous single nucleotide polymorphisms: structure-based assessment of amino acid variation. *Journal of molecular biology*. 2001;307(2):683-706.
23. Kucukkal TG, Petukh M, Li L, Alexov E. Structural and physico-chemical effects of disease and non-disease nsSNPs on proteins. *Current opinion in structural biology*. 2015;32:18-24.
24. Thomas R, McConnell R, Whittaker J, Kirkpatrick P, Bradley J, Sandford R. Identification of mutations in the repeated part of the autosomal dominant polycystic kidney disease type 1 gene, PKD1, by long-range PCR. *American journal of human genetics*. 1999;65(1):39-49.
25. Lee EH, Park JH, Coe CJ, Hahn SH. A novel mutation in the beta-hexosaminidase beta-subunit gene in a 14-month-old Korean boy with Sandhoff disease: first reported Korean case. *Human mutation*. 2000;16(2):180-1.
26. Bajard A, Chabaud S, Cornu C, Castellan AC, Malik S, Kurbatova P, et al. An in silico approach helped to identify the best experimental design, population, and outcome for future randomized clinical trials. *Journal of clinical epidemiology*. 2016;69:125-36.
27. Benson DA, Cavanaugh M, Clark K, Karsch-Mizrachi I, Lipman DJ, Ostell J, et al. GenBank. *Nucleic acids research*. 2017;45(D1):D37-d42.
28. Artimo P, Jonnalagedda M, Arnold K, Baratin D, Csardi G, de Castro E, et al. ExPASy: SIB bioinformatics resource portal. *Nucleic acids research*. 2012;40(Web Server issue):W597-603.
29. Sim NL, Kumar P, Hu J, Henikoff S, Schneider G, Ng PC. SIFT web server: predicting effects of amino acid substitutions on proteins. *Nucleic Acids Res*. 2012;40(Web Server issue):W452-7.
30. Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, Bork P, et al. A method and server for predicting damaging missense mutations. *Nature methods*. 2010;7(4):248-9.
31. Choi Y, Sims GE, Murphy S, Miller JR, Chan AP. Predicting the functional effect of amino acid substitutions and indels. *PloS one*. 2012;7(10):e46688.
32. Hecht M, Bromberg Y, Rost B. Better prediction of functional effects for sequence variants. *BMC genomics*. 2015;16 Suppl 8:S1.
33. Calabrese R, Capriotti E, Fariselli P, Martelli PL, Casadio R. Functional annotations improve the predictive score of human disease-related mutations in proteins. *Human mutation*. 2009;30(8):1237-44.
34. Lopez-Ferrando V, Gazzo A, de la Cruz X, Orozco M, Gelpi JL. PMut: a web-based tool for the annotation of pathological variants on proteins, 2017 update. *Nucleic Acids Res*. 2017;45(W1):W222-W8.
35. Capriotti E, Fariselli P, Casadio R. I-Mutant2.0: predicting stability changes upon mutation from the protein sequence or structure. *Nucleic acids research*. 2005;33(Web Server issue):W306-10.
36. Venselaar H, Te Beek TA, Kuipers RK, Hekkelman ML, Vriend G. Protein structure analysis of mutations causing inheritable diseases. An e-Science approach with life scientist friendly interfaces. *BMC Bioinformatics*. 2010;11:548.
37. Kallberg M, Wang H, Wang S, Peng J, Wang Z, Lu H, et al. Template-based protein structure modeling using the RaptorX web server. *Nat Protoc*. 2012;7(8):1511-22.

38. Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, Meng EC, et al. UCSF Chimera--a visualization system for exploratory research and analysis. *J Comput Chem.* 2004;25(13):1605-12.
39. Bhattacharya A, Ziebarth JD, Cui Y. PolymiRTS Database 3.0: linking polymorphisms in microRNAs and their target sites with human diseases and biological pathways. *Nucleic Acids Res.* 2014;42(Database issue):D86-91.
40. Warde-Farley D, Donaldson SL, Comes O, Zuberi K, Badrawi R, Chao P, et al. The GeneMANIA prediction server: biological network integration for gene prioritization and predicting gene function. *Nucleic Acids Res.* 2010;38(Web Server issue):W214-20.
41. Gaignard P, Fagart J, Niemir N, Puech JP, Azouguene E, Dussau J, et al. Characterization of seven novel mutations on the HEXB gene in French Sandhoff patients. *Gene.* 2013;512(2):521-6.
42. Maegawa GH, Stockley T, Tropak M, Banwell B, Blaser S, Kok F, et al. The natural history of juvenile or subacute GM2 gangliosidosis: 21 new cases and literature review of 134 previously reported. *Pediatrics.* 2006;118(5):e1550-62.
43. Gort L, de Olano N, Macias-Vidal J, Coll MA, Spanish GMWG. GM2 gangliosidoses in Spain: analysis of the HEXA and HEXB genes in 34 Tay-Sachs and 14 Sandhoff patients. *Gene.* 2012;506(1):25-30.
44. Hou Y, McInnes B, Hinek A, Karpati G, Mahuran D. A Pro504 --> Ser substitution in the beta-subunit of beta-hexosaminidase A inhibits alpha-subunit hydrolysis of GM2 ganglioside, resulting in chronic Sandhoff disease. *The Journal of biological chemistry.* 1998;273(33):21386-92.
45. Lemieux MJ, Mark BL, Cherney MM, Withers SG, Mahuran DJ, James MN. Crystallographic structure of human beta-hexosaminidase A: interpretation of Tay-Sachs mutations and loss of GM2 ganglioside hydrolysis. *Journal of molecular biology.* 2006;359(4):913-29.
46. Abiri M, Talebi S, Uitto J, Youssefian L, Vahidnezhad H, Shirzad T, et al. Co-existence of phenylketonuria either with maple syrup urine disease or Sandhoff disease in two patients from Iran: emphasizing the role of consanguinity. *Journal of pediatric endocrinology & metabolism : JPEM.* 2016;29(10):1215-9.
47. Kaya N, Al-Owain M, Abudheim N, Al-Zahrani J, Colak D, Al-Sayed M, et al. GM2 gangliosidosis in Saudi Arabia: multiple mutations and considerations for future carrier screening. *Am J Med Genet A.* 2011;155A(6):1281-4.
48. Tamhankar PM, Mistri M, Kondurkar P, Sanghavi D, Sheth J. Clinical, biochemical and mutation profile in Indian patients with Sandhoff disease. *J Hum Genet.* 2016;61(2):163-6.
49. Zampieri S, Cattarossi S, Oller Ramirez AM, Rosano C, Lourenco CM, Passon N, et al. Sequence and copy number analyses of HEXB gene in patients affected by Sandhoff disease: functional characterization of 9 novel sequence variants. *PloS one.* 2012;7(7):e41516.